Among patients with a CYP3A5 *1 allele, only 3/6 (50%) achieved remission, suggesting a possible trend toward reduced response in functional allele carriers, particularly at lower doses.
← all excerpts
Pharmacogenetics of CYP3A5 in Pediatric Patients With Eosinophilic Esophagitis.
1
—
—